S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions

Verve Therapeutics (VERV) Stock Forecast & Price Target

$11.56
-0.56 (-4.62%)
(As of 11/27/2023 ET)
Compare
Today's Range
$11.38
$12.42
50-Day Range
$8.84
$18.70
52-Week Range
$8.22
$24.69
Volume
1.24 million shs
Average Volume
877,908 shs
Market Capitalization
$736.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Verve Therapeutics Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$30.00
159.52% Upside
High Forecast$55.00
Average Forecast$30.00
Low Forecast$13.00
TypeCurrent Forecast
11/28/22 to 11/28/23
1 Month Ago
10/29/22 to 10/29/23
3 Months Ago
8/30/22 to 8/30/23
1 Year Ago
11/28/21 to 11/28/22
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$30.00$30.83$30.83$49.20
Predicted Upside159.52% Upside73.58% Upside74.50% Upside76.48% Upside
Get Verve Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.


VERV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VERV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Verve Therapeutics Stock vs. The Competition

TypeVerve TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.43
2.67
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside159.52% Upside962.84% Upside5,661.31% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/13/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
9/13/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$22.00+63.45%
8/15/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$56.00 ➝ $55.00+222.20%
8/11/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$31.00+72.22%
8/8/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Jubinville
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/13/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$29.00+111.83%
12/15/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell$13.00-42.50%
(Data available from 11/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












VERV Price Target - Frequently Asked Questions

What is Verve Therapeutics's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Verve Therapeutics stock is Hold based on the current 1 sell rating, 2 hold ratings and 4 buy ratings for VERV. The average twelve-month price prediction for Verve Therapeutics is $30.00 with a high price target of $55.00 and a low price target of $13.00. Learn more on VERV's analyst rating history.

Do Wall Street analysts like Verve Therapeutics more than its competitors?

Analysts like Verve Therapeutics less than other Medical companies. The consensus rating for Verve Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how VERV compares to other companies.

Does Verve Therapeutics's stock price have much upside?

According to analysts, Verve Therapeutics's stock has a predicted upside of 76.82% based on their 12-month stock forecasts.

What analysts cover Verve Therapeutics?

Verve Therapeutics has been rated by Cantor Fitzgerald, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:VERV) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -